The Prize4Life Board has made the difficult decision to dissolve the organization. This decision didn't come without significant and extensive thought.
Following the awarding of the $1Mill Treatment Prize in April 2017, we entered a long process - together with our renowned Scientific Advisory Board and other experts - to review the ALS landscape. We reviewed two components:
1. What is missing now to get to a cure, compared to 12 years ago, when we founded Prize4Life.
2. What are other ALS non-profits doing, and can we act in a non-duplicative way.
Indeed, we have identified such a missing piece - supporting early stage ALS companies. Our deep review found that many good research ideas get stuck because there’s not enough seed funding to support their commercialization.
However, during the review process, we also realized something else - that the fragmentation in the ALS landscape hinders the quest to find a cure, because when different patient organizations compete, efficiencies are not optimized.
With that strong belief, we decided to dissolve the organization and transfer our assets to the ALS Association towards their early stage fund - the research gap we have identified. We chose to transfer our assets to the ALS Association because we were impressed with their research efforts and their leadership. We see them as a leader that can unite and coordinate the fragmented ALS landscape and maximize efficiencies. In addition, the ALS Association is the only national non-profit organization fighting Lou Gehrig's Disease on every front. By leading the way in global research, providing assistance for people with ALS through a nationwide network of chapters, coordinating multidisciplinary care through certified clinical care centers, and fostering government partnerships, The ALS Association builds hope and enhances quality of life while aggressively searching for new treatments and a cure.
Thanks for your interest in Prize4Life!